Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Consolidated revenue growth of 9% was driven by a strategic shift toward high-complexity services, including a 20% sequential increase in oncology treatments in Mexico.
Adjusted EBITDA declined 9% due to temporary margin pressures from investments in medical leadership talent in Mexico and billing reconciliation penalties in Peru.
In Mexico, the company successfully secured improved tier classifications with major insurers, which accelerated patient volume recovery following operational enhancements implemented last year.
The Colombia segment demonstrated a successful pivot in payer mix, with risk-sharing agreements now representing 24% of revenue, up from 14% a year ago, enhancing cash predictability.
#adjusted
Consolidated revenue growth of 9% was driven by a strategic shift toward high-complexity services, including a 20% sequential increase in oncology treatments in Mexico.
Adjusted EBITDA declined 9% due to temporary margin pressures from investments in medical leadership talent in Mexico and billing reconciliation penalties in Peru.
In Mexico, the company successfully secured improved tier classifications with major insurers, which accelerated patient volume recovery following operational enhancements implemented last year.
The Colombia segment demonstrated a successful pivot in payer mix, with risk-sharing agreements now representing 24% of revenue, up from 14% a year ago, enhancing cash predictability.
#adjusted
2 months ago
